Oruka Therapeutics (ORKA) Treasury Shares (2013 - 2026)
Oruka Therapeutics' quarterly Treasury Shares came in at $396145.0 in Q1 2026, down 87.03% year-on-year from $3.1 million in Q1 2025, and down 86.92% quarter-over-quarter from $3.0 million in Q4 2025.
Oruka Therapeutics has reported Treasury Shares for 11 years, with the latest figure at $396145.0 in Q1 2026.
- For the quarter ending Q1 2026, Treasury Shares fell 87.03% year-over-year to $396145.0; the trailing twelve-month figure through Mar 2026 stood at $396145.0 (down 87.03% YoY), and the FY2025 full-year result was $3.0 million, down 0.81% from the prior year.
- Treasury Shares for Q1 2026 stood at $396145.0, down from $3.0 million in the prior quarter.
- The five-year high for Treasury Shares was $3.1 million in Q3 2024, with the low at $91000.0 in Q4 2022.
- Average Treasury Shares over 5 years is $1.4 million, with a median of $1.4 million recorded in 2025.
- Year-over-year, Treasury Shares jumped 3256.44% in 2024 and plunged 87.03% in 2026.
- Tracing ORKA's Treasury Shares over 5 years: stood at $91000.0 in 2022, then changed by 0.0% to $91000.0 in 2023, then jumped by 3256.44% to $3.1 million in 2024, then retreated by 0.81% to $3.0 million in 2025, then sank by 86.92% to $396145.0 in 2026.
- The last three Treasury Shares figures came in at $396145.0 (Q1 2026), $3.0 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 265,401.92 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 700,000.00 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 34.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | 396,145.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 396,145.00 |
| Mar 31, 2026 | 396,145.00 |
| Dec 31, 2025 | 3.03 Mn |
| Dec 31, 2025 | 3.03 Mn |
| Sep 30, 2025 | 1.36 Mn |
| Sep 30, 2025 | 1.36 Mn |
| Jun 30, 2025 | 1.49 Mn |
| Jun 30, 2025 | 1.49 Mn |
| Mar 31, 2025 | 3.05 Mn |
| Mar 31, 2025 | 3.05 Mn |
| Dec 31, 2024 | 3.05 Mn |
| Dec 31, 2024 | 3.05 Mn |
| Sep 30, 2024 | 3.05 Mn |
| Sep 30, 2024 | 3.05 Mn |
| Sep 30, 2023 | 91,000.00 |
| Sep 30, 2023 | 91,000.00 |
| Jun 30, 2023 | 91,000.00 |
| Jun 30, 2023 | 91,000.00 |
| Mar 31, 2023 | 91,000.00 |
| Mar 31, 2023 | 91,000.00 |
| Dec 31, 2022 | 91,000.00 |
| Dec 31, 2022 | 91,000.00 |
| Sep 30, 2018 | 233.00 |
| Sep 30, 2018 | 233.00 |
| Jun 30, 2018 | 233.00 |
| Jun 30, 2018 | 233.00 |
| Mar 31, 2018 | 9,738.00 |
| Mar 31, 2018 | 9,738.00 |
| Dec 31, 2017 | 842.00 |
| Dec 31, 2017 | 842.00 |
| Sep 30, 2017 | 15,401.00 |
| Sep 30, 2017 | 15,401.00 |
| Jun 30, 2017 | 15,401.00 |
| Jun 30, 2017 | 15,401.00 |
| Mar 31, 2017 | 24,905.00 |
| Mar 31, 2017 | 24,905.00 |
| Dec 31, 2016 | 30,739.00 |
| Dec 31, 2016 | 30,739.00 |
| Sep 30, 2016 | 32,402.00 |
| Sep 30, 2016 | 32,402.00 |
| Jun 30, 2016 | 46,757.00 |
| Jun 30, 2016 | 46,757.00 |
| Mar 31, 2016 | 56,458.00 |
| Mar 31, 2016 | 56,458.00 |
| Dec 31, 2015 | 62,359.00 |
| Dec 31, 2015 | 62,359.00 |
| Sep 30, 2015 | 71,780.00 |
| Sep 30, 2015 | 71,780.00 |
| Jun 30, 2015 | 629,383.00 |
| Jun 30, 2015 | 629,383.00 |
| Mar 31, 2015 | 627,024.00 |
| Mar 31, 2015 | 627,024.00 |
| Dec 31, 2014 | 67,274.00 |
| Dec 31, 2014 | 67,274.00 |
| Sep 30, 2014 | 481,029.00 |
| Sep 30, 2014 | 481,029.00 |
| Jun 30, 2014 | 610,700.00 |
| Jun 30, 2014 | 610,700.00 |
| Mar 31, 2014 | 610,700.00 |
| Mar 31, 2014 | 610,700.00 |
| Dec 31, 2013 | 59,851.00 |
| Dec 31, 2013 | 59,851.00 |